Ulotaront, a selective TAAR1 agonist with additional 5-HT1A activity, has demonstrated robust efficacy in clinical trials for schizophrenia, showing improvements across symptom domains while exhibiting a markedly more favorable side-effect profile compared with conventional dopamine D2-targeting antipsychotics [45,46,47]. Here, TAAR1 is linked to schizophrenia.